METHOTREXATE INJECTION BP SOLUTION

দেশ: কানাডা

ভাষা: ইংরেজি

সূত্র: Health Canada

সক্রিয় উপাদান:

METHOTREXATE (METHOTREXATE SODIUM)

থেকে পাওয়া:

ACCORD HEALTHCARE INC

এটিসি কোড:

L01BA01

INN (আন্তর্জাতিক নাম):

METHOTREXATE

ডোজ:

25MG

ফার্মাসিউটিকাল ফর্ম:

SOLUTION

রচনা:

METHOTREXATE (METHOTREXATE SODIUM) 25MG

প্রশাসন রুট:

INTRA-ARTERIAL

প্যাকেজ ইউনিট:

2ML/20ML

প্রেসক্রিপশন টাইপ:

Prescription

থেরাপিউটিক এলাকা:

ANTINEOPLASTIC AGENTS

পণ্য সারাংশ:

Active ingredient group (AIG) number: 0107545002; AHFS:

অনুমোদন অবস্থা:

APPROVED

অনুমোদন তারিখ:

2017-06-12

পণ্য বৈশিষ্ট্য

Page 1 of 55
_ _
PRODUCT MONOGRAPH
PR
METHOTREXATE INJECTION BP
25 MG / ML METHOTREXATE (AS METHOTREXATE SODIUM)
FORMULATION WITHOUT PRESERVATIVE
PR
METHOTREXATE INJECTION BP
25 MG / ML METHOTREXATE (AS METHOTREXATE SODIUM)
FORMULATION WITH PRESERVATIVE
Sterile Solution
Antimetabolite and Antirheumatic
Accord Healthcare Inc.
3535 boul. St. Charles suite 704
Kirkland, QC, H9H 5B9
Canada
Date of Revision:
October 30, 2019
Control No. 231320
Page 2 of 55
_ _
_Pr_
_Methotrexate Injection BP, Product Monograph, Accord Healthcare Inc.
_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
.......................................................................................
5
ADVERSE REACTIONS
.......................................................................................................
14
DRUG INTERACTIONS
.......................................................................................................
19
DOSAGE AND ADMINISTRATION
...................................................................................
23
OVERDOSAGE
.....................................................................................................................
34
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 35
STORAGE AND STABILITY
...............................................................................................
37
SPECIAL HANDLING INSTRUCTIONS
............................................................................
38
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................. 39
PART